Purpose:

Retrospective case series, which purpose is to study the functional results after the implantation of two different posterior chamber phakic intraocular lens (IOL) in high myopic eyes.

Methods:

60 eyes have been evaluated, from January 2017 to January 2018. In 30 of them ICL phakic lens was implanted (group A) and in the other 30 IPCL phakic lens was implanted (group B). Predictability, efficiency, safety and visual acuity (VA) were evaluated preoperatively and at least 6 months postoperatively. The VA obtained for both groups was studied, six months after the surgery. The average age of the patient at the time of the surgery was 27.3 years ± 6.8. Intraocular lens power calculations were performed by Staar Surgical AG and Care Group IPCL based on the following variables: manifest and cycloplegic refractions; keratometry; corneal thickness; and anterior chamber depth.

Results:

In the ICL group (group A) the uncorrected postoperative visual acuity (UVA) was in 13 patients of 20/20 (44%), in 8 patients of 20/25 (27%), in 4 patients of 20/30(13%), in 2 patient of 20/40 (7%), in 2 patients of 20/50 (7%), and in 1 patient 20/70(2%). In the IPCL group (group B), uncorrected postoperative visual acuity (UVA) was in 12 patients of 20/20 (40%), in 10 patients of 20/25 (34%), in 3 patients of 20/30 (11%), in 3 patients of 20/40 (11%), in 1 patient of 20/50 (2%), and in 1 patient 20/70(2%). The postoperative UVA was greater than the preoperative BCVA in 15.15% of the eyes, equal in 86.95% and lower in none of the cases.

Conclusions:

The implantation of this phakic intraocular lenses can be an effective and safe method for the treatment of high myopia. The results in this study confirmed the long-term safety, efficacy, and predictability. The results did not differ significantly between ICL or IPCL implantation. Visual Acuity outcomes were very similar in both groups.